Skip to main content

Sigma-Aldrich Buys Biopharmaceutical Product Manufacturer MMB

NEW YORK (GenomeWeb News) - Sigma-Aldrich has acquired the biopharmaceutical contract manufacturer Molecular Medicine BioServices for an undisclosed amount of cash, Sigma said yesterday.
 
Sigma said it bought the Carlsbad, Calif.-based MMB to expand its SAFC Pharma business segment.
 
Sigma said MMB’s $12 million in annualized revenues will help it reach its growth goals, but will have a neutral impact on earnings in 2007.
 
MMB develops and manufactures viral products and offers DNA, RNA, and active ingredients for the production of novel vaccines and gene therapies. The company has 60 employees, a 23,700-square-foot lab and headquarters, and a 21,400-square-foot manufacturing facility.
 
Sigma said it plans to retain all of MMB's existing management and employees.
 
Sigma’s SAFC segment focuses on high-purity inorganics, cell culture products, and other services.
 
SAFC president Frank Wicks said the addition of MMB gives the company "critical capability" to produce viruses, and will complement the company's transgenic extraction and purification facility in St. Louis and a bacterial fermentation lab it is building in Israel.

The Scan

Possibly as Transmissible

Officials in the UK say the B.1.617.2 variant of SARS-CoV-2 may be as transmitted as easily as the B.1.1.7 variant that was identified in the UK, New Scientist reports.

Gene Therapy for SCID 'Encouraging'

The Associated Press reports that a gene therapy appears to be effective in treating severe combined immunodeficiency syndrome.

To Watch the Variants

Scientists told US lawmakers that SARS-CoV-2 variants need to be better monitored, the New York Times reports.

Nature Papers Present Nautilus Genome, Tool to Analyze Single-Cell Data, More

In Nature this week: nautilus genome gives peek into its evolution, computational tool to analyze single-cell ATAC-seq data, and more.